Heron Therapeutics | HRTX - Net Income


Heron Therapeutics reported $-2.95M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
ALKERMES USD -66.48M 115.82M Mar/2026
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
Amarin USD -1.22M 6.51M Dec/2025
ANI Pharmaceuticals USD 29.49M 2.86M Mar/2026
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD -132.73M 163.54M Mar/2026
Eisai JPY -3.25B 20.43B Mar/2026
Emergent BioSolutions USD -261.3M 78.3M Jun/2023
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -163.56M 164.92M Mar/2026
Ligand Pharmaceuticals USD -13.34M 58.13M Mar/2026
Merck USD -4.24B 7.2B Mar/2026
Nektar Therapeutics USD -36.08M 978K Dec/2025
Neurocrine Biosciences USD 197.9M 44.2M Mar/2026
Omeros USD -32.23M 23.81M Sep/2024
Pacira USD 2.92M 1.28M Mar/2026
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Roche Holding CHF 5.47B 1.76B Dec/2025
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Surmodics USD -5.32M 6.22M Jun/2025
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Veracyte USD 28.71M 12.44M Mar/2026
Vertex Pharmaceuticals USD 1.03B 159.7M Mar/2026